4162 智擎 - 😊參加 NET-02試驗(脂質體伊立替康 (nal-IRI...

\ud83d\ude0a參加 NET-02試驗(脂質體伊立替康 (nal-IRI

OX · 2023-01-10T13:40:32Z

\ud83d\ude0a參加 NET-02試驗(脂質體伊立替康 (nal-IRI) 的 II 期試驗/5-氟尿嘧啶 (5-FU)/亞葉酸或多西紫杉醇作為二線治療)的進行性分化不良的肺外神經內分泌癌(PD-EP-NEC)患者的健康相關生活品質(HRQoL) Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy. Journal of Clinical Oncology Vol 40, Issue 28_suppl. 2022 \ud83d\udc4d結論: HRQoL was maintained and potentially improved with nal-IRI/5-FU/folinic acid, but not docetaxel...... https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.28_suppl.293